Citations

Clear

382 citation(s) found for "Li, Man".

Clinical Reasoning: A 43-Year-Old Man With Subacute Onset of Vision Disturbances, Jaw Spasms, and Balance and Sleep Difficulties
Orozco, Emma, Guo, Yong , Chen, John J. , Dubey, Divyanshu , Howell, Bradley, Moutvic, Margaret A., Louis, Erik K. St. , Moutvic, Margaret, St Louis, Erik K, St Louis, E K , Chen, John J , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Neurology | July 6, 2022 | Volume: 99 | Issue: 9 | Pages: 387-392

10.1212/wnl.0000000000200950 | PMID 35794020 Get It

Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial
Packer, Douglas L. , Wilber, David J. , Dyrda, Katia , Nault, Isabelle , Killu, Ammar M. , Kanagasundram, Arvindh N. , Richardson, Travis D. , Stevenson, William G. , Curley, Michael , Investigators, for the SERF, Kapa, Suraj , Dyrda, Katia , Nault, Isabelle , Killu, Ammar M , Kanagasundram, Arvindh , Richardson, Travis , Stevenson, William , Verma, Atul , Curley, Michael , Kapa, Suraj , Verma, Atul , Investigators, for the SERF

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 1, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circep.121.010347 | PMID 35776711 Get It

Background: Ablation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT. Methods: Thirty-two subjects from 6 centers underwent needle electrode ablation. Each had recurrent drug-refractory monomorphic VT after implantable cardioverter defibrillator implantation and prior standard ablation. During the SERF study procedure, one or more VTs were induced and mapped. The SERF needle catheter was used to create intramural lesions at targeted VT site(s). Acute procedural success was defined as noninducibility of the clinical VT after the procedure. Patients underwent follow-up at 30 days, and 3 and 6 months, with implantable cardioverter defibrillator interrogation at follow-up to determine VT recurrence. Results: These refractory VT patients (91% male, 66±10 years, ejection fraction 35±11%; 56% ischemic, and 44% nonischemic) had a median of 45 device therapies (shock/antitachycardia pacing) for VT in the 3 to 6 months pre-SERF ablation. The study catheter was used to deliver an average of 10±5 lesions per case, with an average of 430±295 seconds of radiofrequency time, 122±65 minute of catheter use time, and a procedural duration of 4.3±1.3 hours. Acute procedural success was 97% for eliminating the clinical VT. At average follow-up of 5 months (n=32), device therapies were reduced by 89%. Complications included 2 periprocedural deaths: an embolic mesenteric infarct and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=1). Conclusions: Intramural heated saline needle ablation showed complete acute and satisfactory mid-term control of difficult VTs failing 1 to 5 prior ablations and drug therapy. Further study is warranted to define safety and longer-term efficacy. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03628534 and NCT02994446.
Abstract 3094: Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models
Jessen, Erik , Vu, Diep, Man, Jos de , Buijsman, Rogier C. , Watkins, Ryan, Alva‐Ruiz, Roberto , Conboy, Caitlin B. , Mun, Dong‐Gi , Vu, Diep, Pandey, Akhilesh , Borad, Mitesh J. , Gores, Gregory J. , Smoot, Rory L.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 3094-3094

10.1158/1538-7445.am2022-3094 Get It

Abstract Background: Cholangiocarcinoma is an aggressive malignancy with limited systemic therapeutics. We have recently identified LCK, a non-receptor tyrosine kinase, as a potential therapeutic target in select subtypes of cholangiocarcinoma. Proteomic profiling in other cancer types has proven beneficial in predicting response to systemic therapies. Herein, we present proteomic profiling of cholangiocarcinoma can predict sensitivity to a novel LCK inhibitor in patient derived xenograft models. Methods: Proteins from 28 unique cholangiocarcinoma patient derived xenograft models (PDX) were isolated, labeled with tandem mass tags (TMT) and then analyzed by liquid chromatography and mass spectroscopy (LC/MS). Phosphopeptides were separately evaluated both by Immobilized Metal Affinity Chromatography and pY-enrichment techniques. Following normalization, the global proteome, serine/threonine phosphoproteome, and tyrosine phosphoproteome were analyzed and a proteomic signature was created for each tumor. These signatures were compared to PDX models with known response profiles to NTRC0652-0, an LCK inhibitor (1 resistant and 1 sensitive). The top 200 differentially abundant proteins (log2FC 2.6) were then utilized to develop a sensitive and a resistant signature. Correlation indices were then calculated across the 28 PDX model library. An additional predicted resistant and predicted sensitive model was expanded. Tumor bearing mice were randomized based on tumor volume to either treatment with NTRC (30mg/kg PO daily), n=5, or vehicle, n=4, (10% Kolliphor, 10% DMSO, 80% Water, 2 mol equivalents HCl). Tumors were measured weekly with calipers and then weighed at the end of the study. Results: In the top 200 differentially abundant proteins that represented the proteomic signature there was over representation of proteins with decreased abundance. There were only 12 proteins with higher abundance in the sensitive model as compared to the resistant. Utilizing the signature developed from the global proteomics data, nine tumors were predicted to be sensitive while 17 were predicted to be resistant to NTRC. PDX115 is a an intrahepatic CCA PDX known to contain an IDH1 mutation and was predicted to be resistant by modeling. The model was resistant to single agent NTRC with no demonstrable effect on tumor growth in vivo. PDX175 is a distal CCA PDX and was predicted to be sensitive by modeling. In vivo growth was inhibited by NTRC as compared to vehicle treated mice following two weeks of treatment (983% vs 435%, p=0.03). Additionally, final tumor weight was significantly lower in NTRC treated mice (0.651 g vs 0.317 g, p=0.04). Conclusion: Cholangiocarcinoma proteomic signatures can be used to predict therapeutic response to a novel LCK inhibitor in preclinical models. Whether or not this could be applied to other treatment modalities in cholangiocarcinoma remains to be determined. Citation Format: Ryan Watkins, Roberto Alva-Ruiz, Caitlin Conboy, Dong-Gi Mun, Erik Jessen, Diep Vu, Jos de Man, Rogier Buijsman, Akhilesh Pandey, Mitesh Borad, Gregory Gores, Rory Smoot. Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3094.
Trust the Process: Prolonged Babesia Parasitemia in an Elderly Man with Asplenia from the American Midwest
Ivancich, Marko, Lutwick, Larry I., Lutwick, Larry, Shweta, Fnu

Mayo Clinic

American Journal of Case Reports | June 10, 2022 | Volume: 23 | Issue: No issue available | Pages: No page available

10.12659/ajcr.936326 | PMID 35844076 Get It

Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.
Deek, Mathew Pierre, Sutera, Phillip, Fonteyne, Valérie , Mendes, Adrianna, Phillips, Ryan , Delrue, Louke , Man, Kathia De , Meerleer, Gert De , Deek, Mathew Pierre, Eecken, Kim Van der , Deek, Rebecca A. , Lumen, Nicolaas , Verbeke, Sofie , Song, Daniel Y. , Paller, Channing J. , Joniau, Steven , Lotan, Tamara Levin , Berlin, Alejandro , Siva, Shankar , Ost, Piet , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 5025-5025

10.1200/jco.2022.40.16_suppl.5025 Get It

5025 Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic castration sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes. Here we present long term outcomes of the phase II STOMP and ORIOLE trials and assess the ability of a high-risk (HiRi) mutational signature to provide prognostic and predictive information regarding MDT response. Methods: Patients with omCSPC (< 3 lesions) enrolled on STOMP (n = 62) and ORIOLE (n = 54) randomized to MDT or observation were pooled. The primary endpoint was progression-free survival (PFS) defined as either PSA or radiographic progression, initiation of androgen deprivation, or death. Secondary endpoint was radiographic PFS (rPFS) defined as radiographic progression or death. Both were calculated using the Kaplan-Meier method and stratified by treatment group. Next generation sequencing (NGS) was performed to identify a HiRi mutational signature defined as pathogenic mutations within ATM, BRCA1/2, Rb1, or TP53. Cox proportional hazards regressions were fit to calculate hazard ratios (HR) and assess the prognostic and predictive values of HiRi mutational status. Results: Median follow-up was 52.5 months. Median PFS was prolonged with MDT (11.9 months) compared to observation (5.9 months) with a pooled HR of 0.44 (95% CI, 0.29 – 0.66, p-value < 0.001). MDT was associated with PSA decrease in a majority of patients (84%) as compared to the observation group (41%). On NGS, the incidence of a pathogenic mutation in a HiRi gene was 24.3%. HiRi mutation was prognostic for PFS -- in those without a HiRi mutation median PFS was 11.9 months compared to 5.9 months in those with a HiRi mutation (HR of 1.74, p = 0.06). HiRi mutation was also prognostic for rPFS -- those without a high-risk mutation experienced median rPFS of 22.6 months compared to 10.0 months in those with a high-risk mutation (HR 2.62, p < 0.01). Tumors without a HiRi mutation treated with MDT experienced the longest PFS (13.4 months) while those with a HiRi randomized to observation experienced the shortest PFS (2.8 months). Stratifying by both treatment arms and HiRi status appeared to show a differential benefit to MDT, with those with HiRi mutations experiencing a larger relative magnitude of benefit to treatment: (HiRi mutation: HR of 0.05, p < 0.01; no HiRi mutation: HR of 0.42, p = 0.01; p interaction, 0.12) suggesting a HiRi mutational status can provide information regarding differential response to treatment. Conclusions: Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained benefit to MDT over observation. A HiRi mutational signature appears prognostic for outcomes in omCSPC and those with HiRi might have a relatively larger magnitude of response to MDT. Future studies are needed to optimize patient selection. Clinical trial information: NCT02680587.
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man
Arora, Nitika, Leavitt, Jacqueline A., Chen, John J. , Leavitt, Jacqueline, Chen, John J

Mayo Clinic

JAMA Neurology | June 6, 2022 | Volume: 79 | Issue: 7 | Pages: 724

10.1001/jamaneurol.2022.1320 | PMID 35666523 Get It

Case 13-2022: A 56-Year-Old Man with Myalgias, Fever, and Bradycardia
Paras, Molly L., Foldyna, Borek, Huang, Alex L., Hohmann, Elizabeth L., Cooper, Leslie T., Christensen, Bianca B., Khurshid, Shaan , Paras, Molly L., Foldyna, Borek, Huang, Alex L., Hohmann, Elizabeth L., Cooper, Leslie T., Christensen, Bianca B.

Mayo Clinic

New England Journal of Medicine | April 27, 2022 | Volume: 386 | Issue: 17 | Pages: 1647-1657

10.1056/nejmcpc2201233 | PMID 35476654 Get It

The Effect of Diabetes-Associated Variation in TCF7L2 on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched
Adams, J.D. , LAURENTI, MARCELLO C. , Wismayer, Daniel Schembri, Bailey, Kent R. , Man, Chiara Dalla , Vella, Adrian , Adams, Jon D, Egan, Aoife M. , Schembri Wismayer, Daniel, Vella, Adrian , Dalla Man, Chiara , Cobelli, Claudio

Mayo Clinic

Metabolic Syndrome and Related Disorders | April 20, 2022 | Volume: 20 | Issue: 6 | Pages: 329-335

10.1089/met.2021.0136 | PMID 35442800 Get It

Case 10-2022: A 78-Year-Old Man with Marked Ventricular Wall Thickening
Lubitz, Steven A. , Tsang, Teresa S.M. , Tower‐Rader, Albree, Karaa, Amel , Dudzinski, David M. , Lubitz, Steven A , Tower-Rader, Albree, Karaa, Amel , Pellikka, Patricia A.

Mayo Clinic

New England Journal of Medicine | March 30, 2022 | Volume: 386 | Issue: 13 | Pages: 1266-1276

10.1056/nejmcpc2201230 | PMID 35353965 Get It

The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction
Bovenkamp, Arno A. van de , Wijkstra, Niels, Oosterveer, Frank, Noordegraaf, Anton Vonk , Bogaard, Harm Jan , Rossum, Albert C. van , Man, Frances S. de , Borlaug, Barry A. , Handoko, M. Louis , van de Bovenkamp, Arno A , Vonk Noordegraaf, Anton , van Rossum, Albert C , de Man, Frances S , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | March 21, 2022 | Volume: 15 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.121.008935 | PMID 35311526 Get It

Background: Because of limited accuracy of noninvasive tests, diastolic stress testing plays an important role in the diagnostic work-up of patients with heart failure with preserved ejection fraction (HFpEF). Exercise right heart catheterization is considered the gold standard and indicated when HFpEF is suspected but left ventricular filling pressures at rest are normal. However, performing exercise during right heart catheterization is not universally available. Here, we examined whether pulmonary capillary wedge pressure (PCWP) during a passive leg raise (PLR) could be used as simple and accurate method to diagnose or rule out occult-HFpEF. Methods: In our tertiary center for pulmonary hypertension and HFpEF, all patients who received a diagnostic right heart catheterization with PCWP-measurements at rest, PLR, and exercise were evaluated (2014–2020). The diagnostic value of PCWP PLR was compared with the gold standard (PCWP EXERCISE ). Cut-offs derived from our cohort were subsequently validated in an external cohort (N=74). Results: Thirty-nine non-HFpEF, 33 occult-HFpEF, and 37 manifest-HFpEF patients were included (N=109). In patients with normal PCWP REST (<15 mmHg), PCWP PLR significantly improved diagnostic accuracy compared with PCWP REST (AUC=0.82 versus 0.69, P =0.03). PCWP PLR ≥19 mmHg (24% of cases) had a specificity of 100% for diagnosing occult-HFpEF, irrespective of diuretic use. PCWP PLR ≥11 mmHg had a 100% sensitivity and negative predictive value for diagnosing occult-HFpEF. Both cut-offs retained a 100% specificity and 100% sensitivity in the external cohort. Absolute change in PCWP PLR or V-wave derived parameters had no incremental value in diagnosing occult-HFpEF. Conclusions: PCWP PLR is a simple and powerful tool that can help to diagnose or rule out occult-HFpEF.